SOUTH SAN FRANCISCO, Calif., April 05, 2016 (GLOBE NEWSWIRE) -- FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that it has appointed Rekha Hemrajani as Chief Operating Officer. She joins an experienced management team including Paul Kassner, Ph.D., Vice President, Quantitative Biology; David Wustrow, Ph.D., Vice President, Drug Discovery; Jordan Fridman, Ph.D., Chief Scientific Officer; William Ho, M.D., Ph.D., Chief Medical Officer; and Brian Wong, M.D., Ph.D., President and Chief Executive Officer.
"We are delighted to welcome Rekha to the management team at FLX Bio as the company advances its growing immuno-oncology and targeted oncology pipeline,” said Dr. Wong. “She brings extensive experience in biopharmaceutical corporate business development and financial operations that will be a great asset to our organization."
Hemrajani joins FLX Bio from 3-V Biosciences, where she served as Chief Financial Officer and Senior Vice President of Business and Financial Operations. Prior to her role at 3-V Biosciences, she served as Vice President, Head of Licensing and Mergers and Acquisitions at Onyx Pharmaceuticals, where she was responsible for corporate development strategy, search and evaluation, financial forecasting and analysis, competitive intelligence and transaction execution. Prior to Onyx, Hemrajani served as Vice President of Business Development at Exelixis, where she was involved in raising more than $800 million in capital through business development and other non-dilutive transactions. She has also served as a consultant to biotech companies and investors and has spent six years in investment banking at Credit Suisse First Boston and Lehman Brothers, helping companies of all sizes in the biopharmaceutical and healthcare industries raise capital in the public and private markets.
Hemrajani received her B.S. degree in Economics and Computer Science from the University of Michigan and her Master of Management degree from the Kellogg Graduate School of Management at Northwestern University.
About FLX Bio
Founded in 2015 following the acquisition of its predecessor company, Flexus Biosciences, Inc., by Bristol-Myers Squibb, FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents. The company leverages its unique insights into tumor pathways to develop novel oral medicines that activate the immune response to eliminate cancer cells.
Located in South San Francisco, Calif. and funded by leading investors, including Kleiner Perkins Caufield & Byers (KPCB), The Column Group (TCG), and Celgene, FLX Bio has assembled a management and leadership team with a proven track record of success and with substantial knowledge and expertise in the tumor microenvironment, drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.